Immunohistochemical Evaluation of Skin Before and After Micro-Ablative Fractional Erbium-Doped Yttrium Aluminum Garnet Laser Treatment

Odo, Lilian Mayumi; Odo, Marina Emiko Yagima; Guedes, Fernanda; Sotto, Mírian Nacagami; Cucé, Luiz Carlos

doi:10.1111/j.1524-4725.2010.01859.x

Cited by 1 publication

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical studies reporting on laser-induced immune activity vary in study design and investigated immune markers. In contrast to the preclinical studies where most studies report on cellular infiltration, clinical studies primarily describe laser-mediated alterations in chemokines [ 44 ], interleukins [ 44 ], lymphocytes [ 40 , 42 ], growth factors [ 40 , 41 ], TLRs [ 43 ] and heat shock proteins (HSPs) [ 40 ].…”

Section: Immunological Responses To Laser: Clinical Evidencementioning

confidence: 99%

“…Results are varied, favoring both inhibited and enhanced immune reactions. In one study assessing the immunology of healthy skin after laser treatment, reduction of Langerhans cells and TLR2 and TLR9 but increased TLR3 expression on day 7 was shown [ 43 ]. TLRs are expressed in innate immune cells such as dendritic cells and macrophages and play crucial roles in the innate immune system with bridging to adaptive immunity.…”

Section: Immunological Responses To Laser: Clinical Evidencementioning

confidence: 99%

See 1 more Smart Citation

Laser Immunotherapy: A Potential Treatment Modality for Keratinocyte Carcinoma

Omland

Wenande

Svane

et al. 2021

Cancers

View full text Add to dashboard Cite

The role of the immune system in cancer growth is well recognized and the development of immunotherapy represents a breakthrough in cancer treatment. Recently, the use of systemic immunotherapy was extended to keratinocyte carcinoma (KC), specifically locally advanced and metastasizing basal and squamous cell carcinoma. However, since most KC lesions are non-aggressive, systemic treatment with associated side effects is rarely justified. Conversely, topical immunotherapy with imiquimod remains restricted to premalignant and superficial lesions. Use of laser in the treatment of KC has evolved from physical tumor destruction and laser-assisted drug delivery to laser-mediated immune modulation. Evidence indicates that laser monotherapy can lead to immune cell infiltration, tumor reduction and resistance to tumor re-inoculation. Combining laser with immunotherapeutic agents, termed laser immunotherapy (LIT), may further potentiate immune activation and tumor response. Studies on LIT show not only direct anti-tumor effects but systemic adaptive immunity, illustrated by the prevention of tumor recurrence and regression in distant untreated tumors. These findings imply a therapeutic potential for both local and metastatic disease. This work provides rationales for immune-based treatment of KC and presents the current status of KC immunotherapy. Aiming to expand the field of KC immunotherapy, the review discusses the literature on immune activation following laser monotherapy and LIT.

show abstract